stockportfolio.pro
Perrigo Company plc (PRGO)
Healthcare · Drug Manufacturers - Specialty & Generic · NYSE
Perrigo Company plc revenue & earnings — last 10 fiscal years
| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $5.28B | $4.95B | $4.73B | $3.87B | $4.09B | $4.14B | $4.45B | $4.66B | $4.37B | $4.25B |
| Gross profit | $2.05B | $1.98B | $1.83B | $1.43B | $1.49B | $1.42B | $1.46B | $1.68B | $1.54B | $1.49B |
| Net income | $-4.01B | $119.60M | $131.00M | $146.10M | $-162.60M | $-68.90M | $-140.60M | $-12.70M | $-171.80M | $-1.43B |
| Net margin | -76.0% | 2.4% | 2.8% | 3.8% | -4.0% | -1.7% | -3.2% | -0.3% | -3.9% | -33.5% |
Source: Perrigo Company plc SEC filings (10-K). 14 years of history available in the interactive view.
What growth is priced into PRGO stock?
At today's market cap of $1.56B, Perrigo Company plc is priced for free-cash-flow growth of about -0.9% per year for 10 years (assuming a 10% discount rate and 2.5% terminal growth, base FCF $145.10M from the FY ending 2025-12-31). For comparison, free cash flow actually grew -20.8%/yr over the last five fiscal years and revenue 0.8%/yr, computed from its SEC filings. This is a reverse DCF — a translation of the price into a growth assumption you can judge, not a fair value and not advice. Change the assumptions yourself in the interactive view →
Explore 14 years of Perrigo Company plc financials — interactive
Full income statement, balance sheet and cash flow with CAGR and trend on every row, 48 quarters, valuation ratios, plain-English health checks, and Ask — our SEC-grounded research assistant.
Open the interactive view — freeOr start a 7-day free trial to track PRGO in your portfolio →
Perrigo Company plc financial history by metric
About Perrigo Company plc
Perrigo Company plc provides over-the-counter health and wellness solutions in the United States, Europe, and internationally. The company operates through Consumer Self-Care Americas and Consumer Self-Care International segments. It offers upper respiratory products, including cough suppressants, expectorants, and sinus and allergy relief; nutrition products consisting of infant formulas and oral electrolyte beverages; digestive health products, including antacids, anti-diarrheal, and anti-heartburn; pain and sleep-aids products comprising pain relievers and fever reducers; and oral care products, which include toothbrushes, toothbrush replacement heads, floss, flossers, whitening products, and toothbrush covers. The company also offers healthy lifestyle products, such as smoking cessation and well-being products; skin care products consisting of dermatological care, scar management, lice treatment, and other products for various skin conditions; women's health products comprising feminine hygiene and contraceptives; vitamins, minerals, and supplements; and other miscellaneous self-care products. It sells its products under the Compeed, Dr. Fresh, Firefly, Good Sense, Good Start, Mederma, Nasonex, Plackers, Prevacid24HR, REACH, Rembrandt, Steripod, Opill, Solpadeine, Coldrex, Physiomer, NiQuitin, ACO, ellaOne, and Compeed brands. The company also offers contract manufacturing services. It sells its products through retail drug, supermarket, and mass merchandise chains; e-commerce stores; wholesalers; pharmacies; drug and grocery retailers; and para-pharmacies. The company was formerly known as Perrigo Company and changed its name to Perrigo Company plc in December 2013. Perrigo Company plc was founded in 1887 and is headquartered in Dublin, Ireland.
Perrigo Company plc — frequently asked questions
What is Perrigo Company plc's revenue?
Perrigo Company plc (PRGO) reported revenue of $4.25B for fiscal year 2025, down 2.8% from the prior year, according to its SEC filings.
Is Perrigo Company plc profitable?
No — PRGO reported a net loss of $-1.43B in fiscal 2025.
What is PRGO's P/E ratio?
Perrigo Company plc trades at a price-to-earnings ratio of about 0.0 based on the latest data in our nightly-refreshed cache.
How fast is Perrigo Company plc growing?
PRGO's revenue grew at roughly 0.8% per year over the last five fiscal years (compound annual growth rate), computed from SEC-filed statements.
How much debt does Perrigo Company plc have?
As of fiscal year 2025, PRGO carried roughly $3.64B in total debt (short- plus long-term borrowings), per its filed balance sheet.
What is Perrigo Company plc's gross margin?
PRGO's gross margin was 35.1% in fiscal 2025 — gross profit of $1.49B on revenue of $4.25B.
What is Perrigo Company plc's market cap?
Perrigo Company plc (PRGO) has a market capitalization of about $1.56B, based on the latest data in our nightly-refreshed cache.
When does Perrigo Company plc's fiscal year end?
PRGO's fiscal year ends in December. Its most recent annual filing covers the fiscal year ending 2025-12-31.
What growth is priced into PRGO stock?
At today's market cap of $1.56B, Perrigo Company plc is priced for free-cash-flow growth of about -0.9% per year for 10 years (assuming a 10% discount rate and 2.5% terminal growth, base FCF $145.10M from the FY ending 2025-12-31). For comparison, free cash flow actually grew -20.8%/yr over the last five fiscal years and revenue 0.8%/yr, computed from its SEC filings.
Where does this data come from?
All figures are computed from Perrigo Company plc's official SEC filings (10-K and 10-Q), covering 14 years of history, refreshed nightly. stockportfolio.pro does not provide investment advice.